key: cord-0980018-6ktyevlb
authors: Pérez-de-Llano, Luis; Romay-Lema, Eva María; Baloira-Villar, Adolfo; Anchorena, Christian; Torres-Durán, María Luisa; Sousa, Adrián; Corbacho-Abelaira, Dolores; Paz-Ferrin, José; Diego-Roza, Carmen; Vilariño-Maneiro, Laura; Marcos, Pedro J.; Montero-Martínez, Carmen; de la Iglesia-Martínez, Fernando; Riveiro-Blanco, Vanessa; Rodríguez-Núñez, Nuria; Abal-Arca, José; Bustillo-Casado, María; Golpe, Rafael
title: COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation
date: 2021-06-23
journal: PLoS One
DOI: 10.1371/journal.pone.0253465
sha: cdb97e1f2ea26fefc6b82c3b65f52833ce392dca
doc_id: 980018
cord_uid: 6ktyevlb

INTRODUCTION: This study was aimed to identify risk factors associated with unfavorable outcomes (composite outcome variable: mortality and need for mechanical ventilation) in patients hospitalized in Galicia with COVID-19 pneumonia. METHODS: Retrospective, multicenter, observational study carried out in the 8 Galician tertiary hospitals. All Patients admitted with confirmed COVID-19 pneumonia from 1st of March to April 24th, 2020 were included. A multivariable logistic regression analysis was performed in order to identify the relationship between risk factors, therapeutic interventions and the composite outcome variable. RESULTS: A total of 1292 patients (56.1% male) were included. Two hundred and twenty-five (17.4%) died and 327 (25.3%) reached the main outcome variable. Age [odds ratio (OR) = 1.03 (95% confidence interval (CI): 1.01–1.04)], CRP quartiles 3 and 4 [OR = 2.24 (95% CI: 1.39–3.63)] and [OR = 3.04 (95% CI: 1.88–4.92)], respectively, Charlson index [OR = 1.16 (95%CI: 1.06–1.26)], SaO2 upon admission [OR = 0.93 (95% CI: 0.91–0.95)], hydroxychloroquine prescription [OR = 0.22 (95%CI: 0.12–0.37)], systemic corticosteroids prescription [OR = 1.99 (95%CI: 1.45–2.75)], and tocilizumab prescription [OR = 3.39 (95%CI: 2.15–5.36)], significantly impacted the outcome. Sensitivity analysis using different alternative logistic regression models identified consistently the ratio admissions/hospital beds as a predictor of the outcome [OR = 1.06 (95% CI: 1.02–1.11)]. CONCLUSION: These findings may help to identify patients at hospital admission with a higher risk of death and may urge healthcare authorities to implement policies aimed at reducing deaths by increasing the availability of hospital beds.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

In late 2019, a new coronavirus (now called severe acute respiratory syndrome coronavirus 2: SARS-CoV-2) was identified in a number of patients presenting with pneumonia in Wuhan, Hubei province, China, and since then, virtually all countries have been affected by the pandemic. The severity of coronavirus disease-2019 (COVID-19) ranges from mild symptoms of upper respiratory tract infection to severe pneumonia and, although most reported cases are at the mild end of the spectrum, 15% of infected patients develop viral pneumonia and 1-5% of them die [1] . The fatality rate differs considerably across countries and different regions of the same country, most likely reflecting overwhelming of healthcare systems [2] .

Over the past months, we have learnt what risk factors are most likely to impact on the prognosis [3] [4] [5] [6] but it remains to be clarified how the different therapeutic strategies (antivirals, systemic corticosteroids, hydroxychloroquine, tocilizumab, antibiotics) may influence the outcome of the patients [7] [8] [9] .

The aim of this study was to identify clinical, demographic and therapeutic risk factors associated with worse outcomes (mortality and need for mechanical ventilation) in patients hospitalized in Galicia with COVID-19 pneumonia during the spring 2020 outbreak.

Retrospective, multicenter, observational study carried out in the 8 Galician tertiary hospitals (Complexo Hospitalario Universitario de A Coruña, Hospital Universitario Lucus Augusti, Complexo Hospitalario Universitario de Ferrol, Complexo Hospitalario Universitario de Ourense, Complexo Hospitalario Universitario de Vigo, Hospital Policlínico de Vigo, Complexo Hospitalario Universitario de Pontevedra, Complexo Hospitalario Universitario de Santiago). These 8 hospitals cover about 85% of the Galician population. Galicia has a population of 2,699,449 inhabitants (1,298,964 male), with a mean age of 47.2 y (44 y in Spain). It is an ageing population (515,847 over 70), particularly vulnerable to severe COVID-19 infection.

All Patients admitted with confirmed COVID-19 pneumonia from 1st of March to April 24th, 2020 were included. Confirmed COVID-19 infection was defined as: "Clinical criteria (at least, 2 of the following symptoms: fever, cough, headache, myalgias, diarrhea, asthenia) plus detection of SARS-CoV-2 from a clinical specimen using a validated PCR or significant rise of IgG antibody level to SARS-CoV-2 between paired sera plus radiologic infiltrates".

The study was approved by the ethics committee of Galicia (Cod. 2020/239). Data were deidentified for analysis. Informed consent was waived due to the retrospective, non-interventional design of the study and the use of anonymous clinical data for the analysis.

Galicia has a network of 8 tertiary hospitals interconnected with a shared operating system that provides a unified electronic medical record, giving the researchers the opportunity to collect good quality data. Data were processed internally and in pseudonymised form were collected by two independent data managers from the electronic medical records. Demographic data, risk factors for poor outcome (cardiovascular diseases, arterial hypertension, diabetes, chronic bronchial diseases, renal failure, cancer, hepatic failure, Kidney transplantation, other organ transplantation), laboratory data on admission (D dimers, lymphocyte and platelet counts, PaO2, VSG, PCR. . .) and COVID-19 treatments used during admission (antiretroviral drugs, anti-malarial drugs, monoclonal antibodies, systemic corticosteroids, interferon, antibiotics) were collected.

Main outcome variable was a composite of in-hospital death (every death in patients included in this study was allocated to COVID-19 pneumoniae irrespective of secondary complications), and need for mechanical ventilation. Secondary outcome variable was in-hospital death. Category variables are presented in terms of absolute and relative frequencies, median and interquartile range. Normality was evaluated using the Kolmogorov-Smirnov test with Lil-liefords´correction. Between-groups comparisons were made by means of Chi-squared test for categorical variables and either Student's t-test or Mann-Whitney U test for continuous variables, as appropriate.

A multivariable logistic regression analysis was performed in order to identify the relationship between risk factors, therapeutic interventions and the composite results variable. Variables with biological plausibility were entered simultaneously in one single step, without checking. We used the following independent variables: age, sex, crude (non-ageadjusted) Charlson comorbidity index, C-reactive protein (CRP), arterial oxygen saturation (SaO 2 ) and the different treatments used during admission. We also included a ratio ([number of admissions per hospital/number of hospital beds] x 100) as a measure of the hospitals' bed stress. Age, Charlson index, SaO 2 and the ratio of hospitals' bed stress were coded continuously. Sex and treatments were coded dichotomously. CRP was selected as a marker of inflammatory status because it was available for most patients. Because not all hospitals used the same measuring method and reference values for CRP, this variable was coded in each hospital in quartiles.

We performed a sensitivity analysis, using several different models. In these alternative analyses we replaced CRP in the multivariable analysis by the lymphocyte and neutrophils cell count, and also added the platelet count and the procalcitonin values. We used both a method that entered all the variables in the model without checking, and a forward automatic conditional selection method that sequentially entered variables with a p-value < 0.05.

Statistical tests were two-sided and significance was taken at the level of p < 0.05. We used MedCalc Statistical Software version 13.3.3 (MedCalc Software bvba, Ostend, Belgium). Strobe checklists can be found in S1 Appendix. Table 1 shows demographic characteristics of the sample and the prevalence of the main pre-existing comorbidities. The most frequent ones were arterial hypertension (49.7%), diabetes mellitus (20.2%), ischemic heart disease (12.6%) and atrial fibrillation (12.5%).

Mean days from symptom onset to admission was 7.5 ± 5.1 (median 7.0, IQR: 4.0-10.0). The most common symptoms were (S1 Table) : fever (77.6%), cough (74.5%) and dyspnea (53.3%). Laboratory findings at admission are shown in Table 2 Lopinavir/ritonavir was administered to 62.5% of patients, whereas 37.1% received systemic corticosteroids and tocilizumab was prescribed in 9.4% patients. Hydroxychloroquine (400 mg twice daily the first day followed by 200 mg twice daily for five days) and azithromycin (500 mg daily for 5 days) were employed in 91.9% and 79.2% of the patients, respectively (Table 3) . It deserves to be emphasized that the patients who received systemic corticosteroids and 

Prognostic factor of COVID-19 pneumonia Median (IQR) g/L 13.6 (12.5-14.6) 13.6 (12.6-14.6) 13.4 (11.9-14.6) 0.009

No. of patients with data 1289

Median (IQR) (cells x 10 3 /mm3) 5.6 (4.3-7.7) 5.4 (4.3-7.3) 6.3 (4.8-9.2) < 0.0001

No. of patients with data 1163

Median (IQR) (cells x 10 3 /mm3) 4.1 (2.9-6.0) 3.8 (2.8-5.6) 5.1 (3.5-7.9) < 0.0001

No. of patients with data 1281 

No. of patients with data 637 

No. of patients with data 291

tocilizumab had a more severe clinical condition on admission, whilst the ones who received hydroxychloroquine presented with a milder clinical picture (S2 Table) .

Of 

The predictors of mortality or need for mechanical ventilation in the multivariable analysis were as follows ( We carried out an additional analysis using in-hospital mortality as a secondary outcome variable. Results are shown in Table 5 . The association between corticosteroids treatment and an increased risk of death did not reach statistical significance, while there were significant associations between this outcome and age, comorbidity burden, CRP, SaO 2 , hydroxychloroquine and tocilizumab, similar to those found for the main composite outcome variable. The results of the sensitivity analysis for the main outcome variable are shown in S3 and S4 Tables. The results of the analysis did not significantly change in these additional analyses, except for the fact that the ratio admissions/hospital beds consistently and significantly correlated with the outcome [OR: 1.69 (95% CI: 1.02-1.18)]

We found a 17.2% in-hospital mortality in this cohort, formed by patients admitted with COVID-19 pneumonia in 8 tertiary Galician hospitals during the peak of the outbreak in [11] . These rates are lower than the one we observed, but it is worth to mention that not all patients included in those studies were diagnosed as having pneumonia. Mortality figures were also higher in our series than in the Chen´s one (11.1%), but although this cohort was entirely formed by pneumonia-diagnosed patients, it should be remarked that mean age was much lower (55 yrs vs 68 yrs) and PaO2 was higher (72.0 vs 63.9 mmHg), likely reflecting less severe condition at admission [12] . In Spain, Berenguer et al found a 28% mortality rate in 4,035 hospitalized patients with COVID-19 disease, of which 77% presented with infiltrates on chest radiograph [13] . Rubio-Rivas et al reported a mortality that exceeded 15% among 12,066 patients admitted with COIVD-19 infection (the rate of those diagnosed with pneumonia has not been specified) in 109 Spanish hospitals [14] . More recently published clinical trials reported mortality rates between 5.1 and 10.4%, but included patients were recruited as late as July 2020 and mean age was considerably lower (55 years) [15, 16] . Data on COVID-19 pneumonia mortality during the second wave are lacking and the scarce available information suggests that mortality rates have declined, at least in developed countries, but this observation could be explained by the fact that second-wave infections tended to affect younger people and it cannot be attributed with certainty to therapeutic advances [17] [18] [19] . Another plausible explanation is provided by Asch and colleagues, who found that the risk-adjusted mortality decreased from 16.56% to 9.29% in the early period of their study (January through April 2020) compared with the later period (May through June 2020), reflecting a possible association between an increased in-hospital mortality and a high prevalence of COVID-19 in the community [20] .

We identified predictors for poor outcome (need for mechanical ventilation or in-hospital death) in patients admitted with Covid-19 pneumonia: old age, low SaO 2 , high CRP values, preexistence of comorbidities and the use of systemic corticosteroids and tocilizumab. Hydroxychloroquine prescription was associated with a favorable outcome.

Increased age has been repeatedly associated with adverse outcome [21, 22] and case fatality rate was reported to be higher in patients with comorbidities, in particular cardiovascular diseases and diabetes [23] [24] [25] [26] . On the other hand, low blood oxygen saturation has also been used to identify severe COVID-19 pneumonia in admitted patients [27] and admission CRP correlated with disease severity and tended to be a good predictor of adverse outcome [28, 29] .

In this study we have found that anti-inflammatory drugs (systemic corticosteroids and tocilizumab) negatively impact on prognosis, even after adjusting for other potential risk factors. In the earlier period of the pandemic, some influential experts advised not to use systemic corticosteroids in patients with COVID-19 pneumonia, relying on the lack of evidence, the negative results observed in influenza pneumonia and impaired clearance of SARS-CoV [30]. Ever since, several studies with an observational design (either retrospective or prospective) yielded contradictory results, with some reporting a positive impact on survival [31] [32] [33] [34] [35] [36] [37] , while others concluding the opposite [38, 39] . The only prospective and randomized clinical trial (although not double-blinded), demonstrated that dexamethasone treatment reduced deaths by one-third in mechanically ventilated patients and by one-fifth in patients receiving oxygen only, whereas no difference in mortality was found in patients who did not need any breathing support [40] . The results of three meta-analysis further support the employ of systemic corticosteroids in COVID-19 pneumonia, but it is worth to mention that the weight of RECOVERY trial was more than 50 per cent in all of them and the magnitude of the effect was modest (OR ranging from 0.70 to 0.88) [41] [42] [43] . On the other hand, several propensity score matching (PSM) studies found no impact of corticosteroids on COVID-19 pneumonia outcome [44] [45] [46] [47] [48] [49] , while an increased mortality was observed in other report [50] and two additional PSM studies concluded that corticosteroid therapy was associated with lower mortality [51, 52] . Therefore, considering all the available evidence, the role of corticosteroids remains controversial in non-critically ill patients who need supplemental oxygen. The evidence for the use of tocilizumab is far less, since only non-randomized single-arm studies and case-series were published with promising results [36, [53] [54] [55] . Recently published studies seem to indicate that tocilizumab has additional benefit to corticosteroids in patients with clinically progressive disease [56, 57] , whereas this treatment did not result in significantly lower mortality than placebo when given as monotherapy in most of the included patients [58] .

In contrast, we have found a protective effect of hydroxychloroquine on death or need for mechanical ventilation, whilst investigators of the Recovery Trial reported that results convincingly exclude any significant mortality advantage of hydroxychloroquine in hospitalized COVID-19 patients [59] .

Therefore, our results seem to be counterintuitive and two explanations can be put forward to account for these differences. The first one is obvious: in our population, corticosteroids and tocilizumab worsen the prognosis of patients with COVID-19 pneumonia. In fact, we have performed an exhaustive regression analysis containing significant covariates in an attempt to simultaneously adjust for their effect with the hope of isolating the impact of the intervention. The second explanation has to do with the inherent drawback of retrospective studies: the existence of potential bias and/or confounders. It is important to note that the captured data reflect the patients´clinical condition at the moment of admission, but this situation changes over time, with some patients improving and some deteriorating, and this surely influences the physician´s decision to prescribe or not a given drug. Since this study was not performed under a controlled condition and treatments were not randomly assigned, we acknowledge that confounding by indication may still persist. Indeed, anti-inflammatory treatment was prescribed in patients with a more severe clinical condition and statistical adjustment for known confounders may not suffice to arrive at 2 groups that have truly the same prognosis at baseline (or, maybe more importantly, in the precise moment that the drug was administered). With hydroxychloroquine it happened exactly the opposite: it was given to patients with less severe disease.

Interestingly, we found that hospital stress was associated with a higher risk of unfavorable outcomes in sensitive analysis, applying different regression schemes (S3 and S4 Tables). A total of 178 out of the 225 deceased patients did not receive mechanical ventilation, but the decision making was not influenced by a lack of ICU resources and clinical criteria based on the likelihood of survival were applied in every case. Although we are not aware of prior studies reporting the association between hospital burden and mortality in patients with COVID-19, this is plausible because hospitals perform worse when they are overwhelmed. Nonetheless, it has been published that the quality of public health systems might be decisive in determining health benefits against pandemics [60] . Moreover, death rate in the North of Italy was twice as high as in the Center-South (13.03% and 6.65%, respectively) during the earlier phase of the current COVID-19 pandemic, likely reflecting a lower hospital stress in the latter (0.81 and 0.20, respectively) [61] .

The study's strengths include the large sample size and the homogeneity of the included population (all patients had microbiologically proven COVID-19 infection and were radiologically diagnosed with pneumonia). Besides, the fact that all Galician hospitals share the same model of electronic medical record enabled us to include every patient admitted to hospital during the study period. Baseline demographic, clinical and laboratory characteristics, alongside the presence of significant comorbidities were individually and exhaustively studied. We also evaluated the effectiveness of viral and host-targeted medications. The main limitation is its retrospective character leading to missing data. Moreover, as aforementioned, studies with retrospective design are not the most accurate to evaluate the impact of treatment on prognosis and survival, due to the possible presence of unnoticed and uncontrolled confounders. Another limitation lies in the unavailability of certain variables that would have been of interest for the aim of our study, such as body mass index.

In conclusion, we identified several predictors of mortality (age, comorbidities, CRP and SpO2 values, the hospitals' burden, the use of corticosteroids and tociluzumab, and the non-use of hydroxychloroquine) among a large cohort of COVID-19 pneumonia patients consecutively admitted to hospitals in Galicia (Spain) during the first outbreak of the epidemic. These findings offer a valuable insight into the characteristics and outcome of patients hospitalized with COVID-19 pneumonia. Our results also suggest that countries have the opportunity to implement policies aimed at reducing deaths by increasing the availability of hospital beds. Results concerning the efficacy of treatments should be interpreted with caution and more welldesigned prospective studies are needed to clarify the role of the different therapies in this clinical context. Supporting information S1 Appendix. STROBE statement-checklist of items that should be included in reports of observational studies. (DOCX) S1 POVISA (Vigo). The authors also acknowledge Javier Muñiz García and Teresa Pérez Castro for their support in the statistical analysis, and Carlos Fernández Lamela for his great effort in collecting the data from the medical records.

WHO Coronavirus Disease (COVID-19) Dashboard. Available online

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Covid-19: risk factors for severe disease and death

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV-2: a prospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia

Hospitalized Patients from the Spanish Registry SEMI-COVID-19

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation

First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus

COVID-19 second wave mortality in Europe and the United States

Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Prolonged Low-Dose Methylprednisolone in Patients with Severe COVID-19 Pneumonia

Efficacy of corticosteroids in nonintensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region

Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: a multicenter retrospective cohort study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study

Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report

Drug treatments for covid-19: living systematic review and network meta-analysis

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study

Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients

The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study

Systemic Corticosteroids and Mortality in Severe and Critical COVID-19 Patients in Wuhan

Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study

Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

What makes health systems resilient against infectious disease outbreaks and natural hazards? Results from a scoping review

How to Minimize the Impact of Pandemic Events: Lessons From the COVID-19 Crisis

The authors acknowledge co-investigators Alberto Fernández-Villar, from the Pneumology Service, Hospital Alvaro Cunqueiro (Vigo), Ana Cobas-Paz, from the Pneumology Service, Hospital POVISA (Vigo) and Fernando Iglesias-Río, from the Pneumology Service, Hospital